Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Deferasirox in Transfusional Iron Overload
NCT00379483Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2002
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in Transfusional Iron Overload (TIO), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of ICL670 at 5 years. Started Jul 2002; status: completed.
02
Drugs
deferasirox
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT00379483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379483.